INTERNATIONAL MULTI DISCIPLINARY JOURNAL FOR RESEARCH & DEVELOPMENT
eISSN 2394-6334 Impact factor: 8.854 Volume 13, issue 04 (2026)

UROLITHIASIS: A COMPREHENSIVE REVIEW OF MODERN DIAGNOSTIC AND TREATMENT APPROACHES

Bahromov Bekzod Shavkatovich
Asian International University, Bukhara, Uzbekistan

ABSTRACT

Urolithiasis (urinary stone disease) affects approximately 10–15% of the global population and represents one of the most prevalent urological conditions worldwide. The pathogenesis involves complex interactions between metabolic, dietary, genetic, and environmental factors leading to supersaturation and crystallization within the urinary tract. This review examines contemporary diagnostic modalities and treatment strategies for urolithiasis, including conservative pharmacological management, extracorporeal shock wave lithotripsy (ESWL), ureteroscopy with laser lithotripsy, percutaneous nephrolithotomy (PCNL), and emerging minimally invasive techniques. Special attention is given to individualized patient selection criteria, evidence-based outcomes, complication profiles, and recurrence prevention protocols. Recent advances in laser technology, robotic-assisted surgery, and artificial intelligence–guided stone analysis are also discussed. A comprehensive, patient-centered approach integrating metabolic evaluation and dietary modification remains the cornerstone of long-term stone disease management.

Keywords: urolithiasis, kidney stones, ESWL, ureteroscopy, PCNL, laser lithotripsy, nephrolithiasis, stone disease management

1. Introduction

Urinary stone disease — encompassing nephrolithiasis (kidney stones), ureterolithiasis, and cystolithiasis — remains one of the most common urological conditions confronting clinicians worldwide. Epidemiological studies estimate a global prevalence of 10–15%, with recurrence rates approaching 50% within five years of the initial stone event in the absence of preventive intervention. The economic burden is substantial, with millions of emergency department visits annually attributed to ureteral colic.

The pathophysiology of stone formation is multifactorial. Supersaturation of the urine with stone-forming solutes — including calcium oxalate, calcium phosphate, uric acid, struvite, and cystine — initiates crystallization. Risk factors include inadequate fluid intake, dietary excesses of sodium, animal protein and oxalate, metabolic disorders such as primary hyperparathyroidism and renal tubular acidosis, recurrent urinary tract infections, anatomical anomalies, and genetic predispositions.

Over the past four decades, the management of urolithiasis has been transformed by innovations in endoscopy, laser physics, shock wave technology, and imaging. This review synthesizes current evidence regarding optimal diagnostic workup, treatment selection, and long-term recurrence prevention strategies, with emphasis on minimally invasive and technology-driven approaches.

2. Epidemiology and Stone Composition

Calcium-containing stones represent the largest proportion of all stone types. Calcium oxalate monohydrate (whewellite) and calcium oxalate dihydrate (weddellite) together account for approximately 65–80% of stones, followed by calcium phosphate (apatite) stones (15–25%). Uric acid stones comprise 5–15% of cases and are strongly associated with hyperuricosuria, acidic urinary pH, and metabolic syndrome. Struvite (magnesium ammonium phosphate) stones, representing 10–15%, develop in the setting of urease-producing bacterial infections (Proteus, Klebsiella, Pseudomonas species) and frequently form staghorn calculi. Cystine stones occur in 3–5% of adults, resulting from an autosomal recessive defect in renal tubular cystine transport.

Geographic and climate factors significantly influence prevalence. The so-called "stone belt" regions — characterized by hot, arid climates — demonstrate the highest incidences. Occupational exposure (outdoor workers, kitchen staff), obesity, type 2 diabetes mellitus, and the metabolic syndrome have emerged as independent risk factors in contemporary epidemiological analyses.

3. Diagnostic Evaluation

3.1 Imaging

Non-contrast computed tomography (NCCT) of the abdomen and pelvis has become the gold standard for evaluating acute flank pain and suspected urolithiasis. Its sensitivity (90–94%) and specificity (92–96%) are superior to all other imaging modalities. NCCT delineates stone location, size, density (Hounsfield units), and anatomical relationships, enabling treatment planning. The stone density and skin-to-stone distance are clinically meaningful predictors of ESWL success.

Renal ultrasonography is the preferred first-line modality in pregnant patients, children, and for radiation-sensitive follow-up imaging. High-frequency probes and color Doppler (to assess the twinkling artifact) improve detection. Magnetic resonance urography offers excellent soft-tissue contrast without radiation but has limited stone detection capability. Plain abdominal radiography (KUB) is suitable only for monitoring radiopaque stones already identified by CT.

3.2 Laboratory Evaluation

Urinalysis with microscopy may reveal hematuria, pyuria, and crystalluria. Urine culture should be obtained whenever infection is suspected. Serum studies include creatinine, electrolytes, uric acid, calcium, phosphate, and complete blood count. A 24-hour urine collection for supersaturation analysis — measuring total volume, pH, calcium, oxalate, citrate, uric acid, sodium, potassium, magnesium, phosphate, sulfate, and ammonium — is recommended for all recurrent stone formers and high-risk first-time formers. Stone analysis by infrared spectroscopy or X-ray diffraction should be performed on all retrieved calculi.

4. Treatment Modalities

Treatment selection is guided by stone size, location, composition, degree of obstruction, patient anatomy, comorbidities, and patient preference. The primary objectives are rapid pain relief, stone clearance, and preservation of renal function.

4.1 Conservative Management and Medical Expulsive Therapy

Spontaneous stone passage is the most common outcome for small ureteral calculi. Stones less than 5 mm pass spontaneously in approximately 68–85% of cases, compared with 47–60% for 5–10 mm stones. Medical expulsive therapy (MET) with alpha-1 adrenergic antagonists — principally tamsulosin (0.4 mg daily) — relaxes smooth muscle in the distal ureter, facilitating stone passage and reducing analgesic requirements. Calcium channel blockers (nifedipine) have also been studied, though evidence is less robust.

For uric acid nephrolithiasis, urinary alkalization to a pH of 6.5–7.0 with potassium citrate or sodium bicarbonate can dissolve stones non-invasively over weeks to months. Allopurinol reduces uric acid production in hyperuricosuric patients. Analgesic management during watchful waiting employs NSAIDs (diclofenac, ketorolac) or opioids for breakthrough pain.

4.2 Extracorporeal Shock Wave Lithotripsy (ESWL)

ESWL remains the only truly non-invasive stone treatment, requiring no anesthetic other than sedation or analgesia. High-energy acoustic shock waves generated by electrohydraulic, electromagnetic, or piezoelectric sources are focused on the stone under fluoroscopic or ultrasound guidance. Fragmentation occurs through compressive and tensile stress mechanisms.

ESWL is most effective for renal stones of 5–15 mm in the renal pelvis or upper/mid ureter. Stone-free rates at 3 months range from 70–90% depending on stone composition and location. Calcium oxalate monohydrate and brushite stones are relatively resistant. Lower pole stones are associated with reduced clearance (55–70%) due to gravitational impairment of fragment elimination. Contraindications include pregnancy, uncorrected coagulopathy, obstruction distal to the stone, aortic or renal artery aneurysm, and active urinary tract infection.

4.3 Ureteroscopy and Laser Lithotripsy

Semi-rigid ureteroscopy is the standard approach for ureteral stones, whereas flexible ureteroscopy (fURS) enables access to all renal calyces. Modern single-use flexible digital ureteroscopes have eliminated sterilization delays and scope damage. The holmium:YAG laser has been the workhorse of endoscopic lithotripsy for over two decades, capable of fragmenting all stone compositions through photothermal ablation.

The Moses technology (pulse modulation) and thulium fiber laser (TFL) represent the most significant recent advances in endoscopic lithotripsy. TFL operates at 1908 nm with a small fiber diameter, enabling higher efficiency, reduced retropulsion, and fine dust fragmentation ("dusting") at high repetition rates. Prospective studies demonstrate TFL stone-free rates exceeding 95% for renal stones up to 20 mm, with shorter operative times compared to holmium laser.

4.4 Retrograde Intrarenal Surgery (RIRS)

RIRS employs a flexible ureteroscope advanced retrogradely through the urethra and ureter into the intrarenal collecting system under fluoroscopic guidance, without percutaneous access. Combined with laser lithotripsy, RIRS achieves stone-free rates of 88–93% for renal stones of 10–20 mm in a single procedure. For intermediate-sized stones (15–20 mm), RIRS is increasingly preferred over PCNL given its superior safety profile, shorter hospital stay (24–48 hours), and equivalent efficacy in experienced hands.

4.5 Percutaneous Nephrolithotomy (PCNL)

PCNL is the treatment of choice for large renal stones (> 20 mm), staghorn calculi, and stones refractory to less invasive approaches. Under fluoroscopic or ultrasound guidance, a percutaneous tract (standard 24–30 Fr, mini 14–20 Fr, ultra-mini 11–13 Fr, micro 4.8 Fr) is created into a targeted renal calyx. Nephroscopy, stone fragmentation (ultrasonic, pneumatic, or laser), and fragment extraction are performed through this access.

Mini-PCNL and ultra-mini PCNL reduce bleeding risk and postoperative pain while maintaining stone-free rates of 92–97% for stones > 20 mm. The CROES multicenter data demonstrated standard PCNL stone-free rates of 75.7% in a single session, with over 90% success after auxiliary procedures. Complications include hemorrhage requiring transfusion or angioembolization (< 3%), collecting system perforation, adjacent organ injury, and sepsis.

4.6 Laparoscopic and Robot-Assisted Surgery

Open and laparoscopic ureterolithotomy or pyelolithotomy is now rarely indicated, reserved for anatomically complex cases, concomitant reconstruction, or failure of all endoscopic approaches. Robot-assisted laparoscopic pyelolithotomy (Da Vinci system) offers improved dexterity and visualization in obese patients or those requiring simultaneous pelviureteric junction repair. Surgical stone-free rates exceed 98%, but operative time and cost are substantially higher than endoscopic alternatives.

5. Special Considerations

5.1 Pregnancy

Urolithiasis complicates approximately 1 in 2,000 pregnancies. Diagnosis relies on ultrasonography and low-dose MRI to minimize fetal radiation exposure. Conservative management with hydration, analgesia, and ureteral stenting or nephrostomy for obstruction is preferred. Ureteroscopy with holmium laser in the second trimester is safe and effective when drainage procedures fail; ESWL and PCNL are contraindicated in pregnancy.

5.2 Pediatric Urolithiasis

Metabolic abnormalities (hypercalciuria, hyperoxaluria, cystinuria) account for a greater proportion of stone disease in children than in adults. Dietary assessment and 24-hour urine studies are essential. Ureteroscopy with miniaturized instruments and ESWL are favored; mini-PCNL is increasingly performed with good outcomes. Metabolic correction is critical to prevent recurrence in the pediatric population.

6. Recurrence Prevention

Recurrence rates of untreated urolithiasis reach 30–50% at five years. General lifestyle measures applicable to all stone formers include:

- High fluid intake (> 2.5 L urine output per day), targeting urine specific gravity < 1.010
- Dietary sodium restriction (< 2,300 mg/day) to reduce calciuria
- Normal calcium intake (1,000–1,200 mg/day from dietary sources) — calcium restriction increases oxalate absorption and paradoxically raises stone risk
- Moderation of animal protein intake (< 0.8–1.0 g/kg/day)
- BMI normalization and regular aerobic exercise

Specific pharmacological prevention is guided by 24-hour urine results and stone composition. Thiazide diuretics (hydrochlorothiazide, chlorthalidone) reduce calcium excretion in hypercalciuria. Allopurinol and dietary protein restriction address hyperuricosuria. Potassium citrate corrects hypocitraturia and urinary alkalinization in uric acid stone disease. Pyridoxine supplementation reduces oxalate production in primary hyperoxaluria type 1.

7. Emerging Technologies and Future Directions

Artificial intelligence (AI) algorithms applied to non-contrast CT datasets can now predict stone composition with accuracy comparable to laboratory analysis, enabling composition-guided treatment planning without stone retrieval. Deep learning models also demonstrate promising results in predicting spontaneous passage probability and ESWL success based on multi-parametric CT features.

Single-use digital flexible ureteroscopes have overcome the limitations of scope sterilization and reprocessing, reducing procedure delays and infection risk. Third-generation thulium fiber lasers with super-pulse modes and real-time feedback continue to expand the boundaries of endoscopic stone fragmentation. Robotic-assisted ureteroscopy platforms under development aim to improve scope stability, reduce surgeon radiation exposure, and enable remote procedures.

Pharmacological dissolution of calcium oxalate stones, historically limited to uric acid calculi, is an active area of investigation. Experimental oxalate-degrading probiotics (Oxalobacter formigenes colonization therapy), reloxaliase (recombinant oxalate decarboxylase), and CRISPR-based correction of primary hyperoxaluria represent promising but largely pre-clinical strategies. Personalized "stone prevention" guided by microbiome profiling and metabolomics is anticipated to enter clinical practice within the next decade.

8. Conclusions

Urolithiasis remains a highly prevalent condition with significant morbidity and economic burden. The management paradigm has evolved from open surgery to a spectrum of minimally invasive techniques capable of treating virtually all stone burdens with high efficacy and low complication rates. Non-contrast CT is the cornerstone of modern imaging, while 24-hour urine studies provide the metabolic foundation for individualized prevention. ESWL, ureteroscopy with laser lithotripsy, RIRS, and PCNL each occupy a defined niche in the treatment algorithm, with selection guided by evidence-based criteria. Recurrence prevention — integrating fluid, dietary, and pharmacological measures — is equally important as acute stone clearance. Ongoing technological innovations in laser systems, AI diagnostics, and robotic endoscopy promise to further optimize outcomes for stone patients worldwide.

REFERENCES

1.Bahromov Bekzod Shavkatovich. (2025). UROLITHIASIS: EPIDEMIOLOGY AND RISK FACTORS. https://doi.org/10.5281/zenodo.15070401

2.ANESTHESIOLOGICAL CARE AND INTENSIVE CARE OF GERONTOLOGICAL PATIENTS IN UROLOGY. (2025). International Journal of Medical Sciences, 5(02), 381-384. https://doi.org/10.55640/

3. SOME PROBLEMS OF UROLOGY IN NEPHROLOGY. (2024). International Journal of Medical Sciences, 4(12), 127-130. https://doi.org/10.55640/

4. PREVENTION OF INTRAOPERATIVE COMPLICATIONS OF ENDOVIDEOSURGICAL INTERVENTIONS IN UROLOGY. (2024). International Journal of Medical Sciences, 4(11), 292-295. https://doi.org/10.55640/

5. ПУТИ УЛУЧШЕНИЯ КАЧЕСТВА НЕОТЛОЖНОЙ ПОМОЩИ БОЛЬНЫМ УРЕТЕРОЛИТИАЗОМ. (2024). International Journal of Medical Sciences, 4(10), 135-138. https://doi.org/10.55640/

6. Bahromov Bekzod Shavkatovich. (2024). Urinary Tract Infection Gonorrhea. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(5), 515–517. Retrieved from https://sciencebox.uz/index.php/amaltibbiyot/article/view/10804

7. Shavkatovich B. B. . (2024). Urinary Tract Infections. Research Journal of Trauma and Disability Studies, 3(4), 249–251. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/2602

8. Bahromov Bekzod Shavkatovich. (2025). PROSTATE CANCER: EPIDEMIOLOGY, RISK FACTORS, DIAGNOSIS. https://doi.org/10.5281/zenodo.15242564

9. URINARY STONE DISEASE: ETIOLOGY, PATHOGENESIS, AND TREATMENT. (2025). International Journal of Medical Sciences, 5(11), 456-458. https://doi.org/10.55640/

10. URINARY TRACT INFECTION (UTI): ETIOLOGY, PATHOGENESIS, DIAGNOSIS, AND TREATMENT. (2025). International Journal of Medical Sciences, 5(12), 735-738. https://doi.org/10.55640/

11. Bahromov Bekzod Shavkatovich. (2025). RISK FACTORS AND DIAGNOSIS OF KIDNEY STONE. https://doi.org/10.5281/zenodo.15515734

12. Shavkatovich, B. B. (2025). UROLITHIASIS: ETIOLOGY AND DIAGNOSTIC APPROACHES. International Journal of Cognitive Neuroscience and Psychology, 3(9), 39–43. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/2124

13. Bahromov Bekzod Shavkatovich. (2025). BENIGN PROSTATIC HYPERPLASIA (BPH). International Journal of Integrative and Modern Medicine, 3(10), 247–250. Retrieved from https://medicaljournals.eu/index.php/IJIMM/article/view/2238

14.CHRONIC PROSTATITIS: ETIOLOGY AND TREATMENT. (2025). International Journal of Medical Sciences, 5(12), 729-733. https://doi.org/10.55640/

15. COMPARISON OF SURGICAL TECHNIQUES FOR BENIGN PROSTATIC HYPERPLASIA: OUTCOMES AND INNOVATIONS. (2025). International Journal of Medical Sciences, 5(11), 551-554. https://doi.org/10.55640/

16. Mansurov Sardor Vali o'g'li. (2025). Neuro-Oncology in Transition: Molecular Classification and Emerging Therapies for Brain Tumors. International Journal of Integrative and Modern Medicine, 3(10), 233–237. Retrieved from https://medicaljournals.eu/index.php/IJIMM/article/view/2235

17. o'g'li, M. S. V. (2025). ESOPHAGEAL CANCER: EPIDEMIOLOGY, PATHOGENESIS, AND MODERN APPROACHES TO MANAGEMENT. International Journal of Cognitive Neuroscience and Psychology, 3(9), 59–64. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/2127

18. Mansurov Sardor Vali o'g'li. (2025). RECENT DEVELOPMENTS IN THE DIAGNOSIS AND TREATMENT OF HEPATITIS: A GLOBAL PERSPECTIVE. https://doi.org/10.5281/zenodo.15478708

19. Mansurov Sardor Vali o'g'li. (2025). URINARY BLADDER CANCER. https://doi.org/10.5281/zenodo.15227539

20. Mansurov Sardor Vali o'g'li. (2025). ACUTE KIDNEY INJURY: ETIOLOGY AND TREATMENT. https://doi.org/10.5281/zenodo.15070424

21. Mansurov Sardor Vali o'g'li. (2025). EPIDEMIOLOGY AND TREATMENT OF RENAL CELL CARCINOMA: IDENTIFYING KEY RISK FACTORS. https://doi.org/10.5281/zenodo.14909826

22. PROSTATE CANCER: PATHOLOGY AND TREATMENT. (2024). International Bulletin of Medical Sciences and Clinical Research, 4(11), 65-70. https://doi.org/10.37547/

23. Mansurov Sardor Vali o'g'li, KIDNEY CANCER: EPIDEMIOLOGY AND TREATMENT , EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE: Vol. 4 No. 11 (2024): European Journal of Modern Medicine and Practice

https://inovatus.es/index.php/ejmmp/article/view/4509

24. Mansurov Sardor Vali o'g'li, SQUAMOUS CELL CARCINOMA OF THE PENIS: EPIDEMIOLOGY AND TREATMENT , EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE: Vol. 4 No. 10 (2024): European Journal of Modern Medicine and Practice https://inovatus.es/index.php/ejmmp/article/view/4245

25. Valiyevich, M. S. . (2024). Specific Morphofunctional Characteristics of the Kidney Caused by Brain Damage in Various Emergency Situations. Research Journal of Trauma and Disability Studies, 3(4), 286–289. Retrieved from http://journals.academiczone.net/index.php/rjtds/article/view/2628

27.ANESTHESIOLOGICAL CARE AND INTENSIVE CARE OF GERONTOLOGICAL PATIENTS IN UROLOGY. (2025). International Journal of Medical Sciences, 5(02), 381-384. https://doi.org/10.55640/

28. SOME PROBLEMS OF UROLOGY IN NEPHROLOGY. (2024). International Journal of Medical Sciences, 4(12), 127-130. https://doi.org/10.55640/

29. BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER: A COMPREHENSIVE COMPARATIVE REVIEW. (2026). *Journal of Multidisciplinary Sciences and Innovations*, *5*(02), 1991-1993. https://doi.org/10.55640/

30.MODERN TREATMENT APPROACHES FOR URINARY STONE DISEASE (UROLITHIASIS). (2026). *Journal of Multidisciplinary Sciences and Innovations*, *5*(01), 802-805. https://doi.org/10.55640/

31.Bahromov Bekzod Shavkatovich. (2026). URINARY BLADDER STONES AND KIDNEY STONES: CLINICAL FEATURES, DIAGNOSIS AND TREATMENT. *Ethiopian International Journal of Multidisciplinary Research*, *13*(03), 671–675. Retrieved from https://www.eijmr.org/index.php/eijmr/article/view/5634